<DOC>
	<DOCNO>NCT01117584</DOCNO>
	<brief_summary>Evaluate efficacy , safety tolerability 12-week treatment 4 dos ASP1941 compare placebo combination metformin adult patient Type 2 Diabetes Mellitus inadequate glycemic control metformin alone .</brief_summary>
	<brief_title>A Study Evaluate Effect ASP1941 Combination With Metformin Adult Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subject diagnose Diabetes Mellitus type 2 ( T2DM ) least 6 month Subject inadequate glycemic control indicate HbA1c level 7.0 % 9.5 % start runin period Visit 1 AND meet FPG discontinuation criterion Subject stable dose least 1500 mg/day metformin monotherapy least 6 week prior Visit 1 Subject stable diet exercise program ( least 6 week prior Visit 1 ) willing remain program duration study Subject body mass index ( BMI ) 20 45 kg/m2 Visit 1 Female subject childbearing potential negative serum pregnancy test ( human chorionic gonadotropin [ hCG ] ) Visit 1 agrees use acceptable form contraception throughout duration study OR least 1 year postmenopausal ( define amenorrhea least 1 year ) surgically sterile . Male study subject advise use male condom addition partner use another acceptable method study 3 month last dose Subject know complication T2DM indicate late disease state investigator 's opinion preclude subject participation Subject type 1 diabetes mellitus Subject need insulin therapy receive insulin within 3 month prior Visit 1 , exception acute use &lt; 7 day Subject serum creatinine high upper limit normal range Visit 1 Subject alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) high 3 time upper limit normal range total bilirubin 2 time upper limit normal Visit 1 Subject urinary microalbumin/creatinine ratio equal 300 mg/g Visit 1 Subject symptomatic urinary tract infection ( UTI ) symptomatic genital infection Visit 1 placebo runin period , include prior randomization Visit 2 Subject persistent , uncontrolled severe hypertension indicate systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg take sit position 5 minute rest least 2 measurement ( within 30 minute ) Visit 1 Subject significant cardiovascular disease , myocardial infarction vascular intervention ( e.g . angioplasty stent ) within 3 month prior Visit 1 , history heart failure ( New York Heart Association [ NYHA ] Class III IV ) Subject know hepatitis carrier hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody ( enzyme link immunosorbent assay [ ELISA ] plus confirmatory test ) , know positive human immunodeficiency virus ( HIV ) HIV1 and/or HIV 2 Subject currently receive exclude medication ( loopdiuretics systemic corticosteroid ) receive oral antidiabetic drug except metformin within 3 month prior Visit 1 Subject history lactic acidosis Subject history drug alcohol abuse/dependency within 12 month prior Visit 1 define Diagnostic Statistical ManualIV ( DSMIV ) Subject malignancy last 5 year , except adequately treat basal squamous cell carcinoma skin carcinoma situ cervix Female subject pregnant , lactate premenopausal positive serum pregnancy test ( hCG ) Visit 1 intention become pregnant Subject unstable medical psychiatric illness Subject know suspected hypersensitivity ASP1941 component formulation use Subject previously receive ASP1941 Subject concurrently participate another drug study receive investigational drug within 30 day ( limit set national law , whichever long ) prior Visit 1 Subject concurrent illness , opinion investigator , may interfere treatment evaluation safety completion study In investigator 's judgment , subject unable adhere treatment regimen , protocol procedure study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>diabetes</keyword>
	<keyword>ASP1941</keyword>
	<keyword>metformin</keyword>
</DOC>